Met-HeFT meta-analysis
2026
In patients with heart failure or ischaemic heart disease in studies of metformin, metformin did not reduce clinical outcomes compared with no metformin.
Resultado
Pooling the randomised evidence in heart failure and in ischaemic heart disease reached the same conclusion as the trial: no significant protection against cardiovascular outcomes with metformin.
- Subtema
- Metabolic therapy
- Desenho
- Meta-analysis of randomised placebo-controlled metformin trials, presented alongside Met-HeFT: 3 trials in heart failure with reduced ejection fraction (1,077 patients, including Met-HeFT) and 4 trials in established ischaemic heart disease (1,123 patients); presenter Anders Hostrup Larsen, Goedstrup Hospital, Herning, Denmark
- Incluídos
- 2200 doentes
- Relevância
- Complementar: contexto, não conhecimento obrigatório.
- Fonte
- Presented at ESC Congress 2026, Hot Line 6, 30 August.
Discussão e crítica
The companion to Met-HeFT, and it lands in the same place: across the randomised evidence in heart failure and in ischaemic heart disease, metformin does not protect against cardiovascular events. Read with the trial, the observational signal that made metformin a cardiovascular drug looks like confounding by who gets prescribed it. Numbers beyond the direction were not in the material released with the presentation; this entry will carry them when the publication appears.